calumniate
发表于 2025-3-25 07:24:36
http://reply.papertrans.cn/55/5427/542675/542675_21.png
感情
发表于 2025-3-25 08:21:32
http://reply.papertrans.cn/55/5427/542675/542675_22.png
按等级
发表于 2025-3-25 14:06:35
Cancer Treatment and Researchhttp://image.papertrans.cn/k/image/542675.jpg
STANT
发表于 2025-3-25 15:57:10
978-1-4613-5083-5Kluwer Academic Publishers 2003
cogitate
发表于 2025-3-25 23:01:27
Kidney Cancer978-1-4615-0451-1Series ISSN 0927-3042 Series E-ISSN 2509-8497
Conducive
发表于 2025-3-26 03:52:16
http://reply.papertrans.cn/55/5427/542675/542675_26.png
口诀法
发表于 2025-3-26 05:35:23
The Role of Systemic Chemotherapy in the Treatment of Kidney Cancerpproximately 10 months with a 3-year survival rate of about 10%.. RCC is typically described as chemotherapy (and radiation therapy) resistant. Most authors agree that biologic response modifiers (i e immunotherapy) represent standard first-line treatment for advanced RCC.
Thyroxine
发表于 2025-3-26 08:52:28
Monoclonal Antibody Therapy of Kidney Cancer once RCC has metastasized, treatment options are very limited. This tumor is not radiosensitive, resistant to chemotherapy, and treatment with biological response modifiers (IL-2, IFN) leads to low response rates.
微生物
发表于 2025-3-26 13:23:05
https://doi.org/10.1007/978-1-4615-0451-1Staging; cancer; carcinoma; cell; genetics; kidney; minimally invasive surgery; molecular genetics; preventi
Salivary-Gland
发表于 2025-3-26 19:09:41
http://reply.papertrans.cn/55/5427/542675/542675_30.png